Bisphosphonates-Related Osteonecrosis of the Jaws

refers to the exposed bone in the maxillofacial region (jaws) that fails to heal within 8 weeks in a patient who Is currently or was previously treated with bisphosphonates, and has not had radiation therapy to the jaws

Incidence

in the early USA the report was 0.8–12% with intravenous BP and 0.7/100,000 (0.0007%) with oral BP

In Europe, the incidence was 95/100,000 (0.095%) with intravenous administration and 1/100,000 (0.001%) with oral administration

in Australia  BRONJ occurred in 1.15% of intravenously administered patients and in 0.04% of the orally administered patients

Taken together, these reports suggest that the incidence of BRONJ with intravenous (IV) BPs has greater risk than oral BPs

References

1-    Tardast, A., Sjöman, R., Løes, S., & Abtahi, J. (2015). Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. Journal of Applied Oral Science, 23(3), 310–314. https://doi.org/10.1590/1678-775720140506

2-    Ficarra, G., & Beninati, F. (2007, April 1). Bisphosphonate – related osteonecrosis of the jaws: the point of view of the oral pathologist. https://pmc.ncbi.nlm.nih.gov/articles/PMC2781184/

3-    Tetsuro Ikebe, Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw,Oral Science International,Volume 10, Issue 1,2013,Pages 1-8, (https://www.sciencedirect.com/science/article/pii/S1348864312000456)

4-    Burket’s Oral Medicine 12th edition by Michal Glick